Complaining about the valuation on Novo Nordisk (NVO)
shares is a fruitless exercise. It's one of the strongest growth
stories in healthcare, and so long as the company continues to execute,
those premium multiples are likely to stay in place. I don't really
embrace the "buy high, sell higher" philosophy, but it's difficult for
me to ignore the growth and potential at this highly-focused
biopharmaceutical company.
Continue reading here:
Novo Nordisk Still A Top-Notch Healthcare Growth Story
No comments:
Post a Comment